{"entity":{"id":"nct06526819","kind":"trial","name":"SMP-3124LP in Adults With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SMP3124LP in advanced solid tumours, run by Sumitomo Pharma America, Inc., now recruiting.","summary":"SMP-3124LP in Adults With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06526819 by Sumitomo Pharma America, Inc., with 120 participants planned, started 2024-08-14 and due to reach its primary completion in 2028-12. Interventions recorded: SMP3124LP.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06526819","url":"https://clinicaltrials.gov/study/NCT06526819"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06526819","phase":"1/2","setting":"An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors","sponsor":"Sumitomo Pharma America, Inc.","enrolled":120,"outcomes":[]},"route":"/trials/nct06526819/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}